Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Susan F. Sencer, MD, PA-C

Children's Hospitals and Clinics of Minnesota - Minneapolis

Intervention

Traumeel S(drug)

Enrollment

195 enrolled

Eligibility

3-25 years · All sexes

Timeline

2004 – 2011

Study locations (30)

• University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
• Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• Stanford Comprehensive Cancer Center at Stanford University Medical Center, Stanford, California, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• University of Florida Shands Cancer Center, Gainesville, Florida, United States
• Nemours Children's Clinic, Jacksonville, Florida, United States
• University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
• All Children's Hospital, St. Petersburg, Florida, United States
• St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States
• Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
• Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
• Indiana University Cancer Center, Indianapolis, Indiana, United States
• Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
• Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06326008
  Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06859424
  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE2, PHASE3NCT06860269
  A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06895538
  Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
  Peking University First Hospital
• RECRUITINGNANCT06960993
  Mosaic Trial for Stem Cell Transplant Recipients
  Northwestern University
• RECRUITINGPHASE2NCT06816134
  Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06608732
  Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
  Institute of Hematology & Blood Diseases Hospital, China
• ACTIVE NOT RECRUITINGNANCT05968963
  Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
  University of Miami

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →